bridgebio pharma secures up to $1.25 billion of capital from blue owl and cpp investments to…
BridgeBio Pharma, Inc. (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced strategic financing from Blue Owl…
Read More...
Read More...